Valuation: Lineage Cell Therapeutics, Inc.

Market Cap 319M 280M 260M 239M 451M 30.51B 461M 3.1B 1.21B 14.99B 1.2B 1.17B 51.82B P/E 2026 *
-17.3x
P/E 2027 * -13.2x
Enterprise Value 319M 280M 260M 239M 451M 30.51B 461M 3.1B 1.21B 14.99B 1.2B 1.17B 51.82B EV / Sales 2026 *
17.8x
EV / Sales 2027 * 17.6x
Free-Float
95.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Lineage Cell Therapeutics, Inc.

1 day-5.47%
1 week-10.37%
Current month-7.63%
1 month-4.72%
3 months-18.24%
6 months-31.25%
Current year-27.54%
1 week 1.21
Extreme 1.21
1.36
1 month 1.2
Extreme 1.2
1.38
Current year 1.18
Extreme 1.18
1.98
1 year 0.93
Extreme 0.9296
2.09
3 years 0.37
Extreme 0.3651
2.09
5 years 0.37
Extreme 0.3651
2.8
10 years 0.37
Extreme 0.3651
4
Manager TitleAgeSince
Chief Executive Officer 54 17/09/2018
Director of Finance/CFO 50 14/11/2022
Chief Operating Officer - 01/12/2010
Director TitleAgeSince
Director/Board Member 60 01/07/2009
Director/Board Member 68 11/04/2014
Chairman 60 27/04/2024
Date Insider Type Main position Quantity % Market Cap.
07-01Free

Director

125,000 0.0501%
07-01Free

Director

125,000 0.0501%
07-01Free

Director

125,000 0.0501%
Change 5-day change 1-year change 3-year change Capi.($)
-5.47%-10.37%+17.48%-12.95% 319M
+0.44%+2.51%+4.36%+10.27% 50.73B
-1.57%-2.80%+383.82%+582.81% 39.73B
-0.14%+0.25%+27.49%-5.23% 34.69B
+1.76%+2.12%+21.44%+58.27% 33.21B
-0.06%-4.63%+2.94%+31.65% 26.76B
-1.93%-3.38% - - 16.8B
-1.49%-4.92%+63.89%+119.25% 15.37B
+0.78%+0.20%+14.69%+17.08% 13.78B
-0.97%-4.02%+10.35%-31.69% 12.85B
Average -0.72%-1.40%+60.72%+85.50% 24.42B
Weighted average by Cap. +0.04%-0.39%+81.51%+122.82%

Financials

2026 *2027 *
Net sales 17.94M 15.76M 14.61M 13.43M 25.38M 1.72B 25.93M 174M 68.14M 843M 67.35M 65.88M 2.91B 18.09M 15.89M 14.74M 13.55M 25.6M 1.73B 26.15M 176M 68.73M 850M 67.94M 66.45M 2.94B
Net income -23.79M -20.9M -19.38M -17.82M -33.66M -2.27B -34.38M -231M -90.37M -1.12B -89.32M -87.37M -3.86B -31.66M -27.81M -25.79M -23.71M -44.8M -3.03B -45.76M -308M -120M -1.49B -119M -116M -5.14B
Net Debt - -
Logo Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).
Employees
75
Date Price Change Volume
13/07/26 $1.210 -5.47% 952,469
10/07/26 $1.280 -0.78% 738,914
09/07/26 $1.290 -3.73% 1,161,891
08/07/26 $1.340 +1.52% 1,377,206
07/07/26 $1.320 -0.75% 680,001
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.210USD
Average target price
5.500USD
Spread / Average Target
+354.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LCTX Stock